Ferring Hails World First Positive Phase III Data For Microbiome Product
US Filing Planned For Later This Year
Preliminary efficacy findings from an ongoing pivotal study of Ferring's RBX2660 showed that the first-in-class microbiota-based therapy helped restore the gut microbiome and break the cycle of recurrence of C diff. infection.
